<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17585" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Angiotensin II Receptor Blockers (ARB)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hill</surname>
            <given-names>Robert D.</given-names>
          </name>
          <aff>Campbell University SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidya</surname>
            <given-names>Prabhakar N.</given-names>
          </name>
          <aff>Campbell University School of OM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Hill declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhakar Vaidya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17585.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pharmaceutical RAAS blockade is a common and successful strategy in treating several diseases, including hypertension, congestive heart failure, and chronic kidney disease of all types, including diabetic nephropathy. Indications for the use of ARBs are similar to those for ACEIs. However, in patients who cannot tolerate ACEI therapy due to an ACEI-induced cough or angioneurotic edema, ARB therapy is appropriate and suggested as an alternative. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of ARB therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with hypertension and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ARBs.</p></list-item><list-item><p>Summarize the indications for ARB therapy and their place in antihypertensive strategy.</p></list-item><list-item><p>Review the need for monitoring and follow-up with ARB therapy, including possible adverse reactions.</p></list-item><list-item><p>Explain the importance of ARB therapy in hypertension management and how it affects therapeutic strategy to improve care coordination and communication among the interprofessional team when using these agents to achieve therapeutic outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17585&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17585">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17585.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The renin-angiotensin-aldosterone system (RAAS) is intricately involved in the pathophysiology of several diseases, including hypertension, congestive heart failure, and chronic kidney disease of all types, including diabetic nephropathy.&#x000a0;Pharmaceutical RAAS blockade has is a common and successful strategy in each of these conditions.<xref ref-type="bibr" rid="article-17585.r1">[1]</xref><xref ref-type="bibr" rid="article-17585.r2">[2]</xref><xref ref-type="bibr" rid="article-17585.r3">[3]</xref>&#x000a0;</p>
        <p>As a class, angiotensin receptor blockers, or ARBs, bind to and inhibit the angiotensin II type 1 receptor and are indicated to treat hypertension, congestive heart failure, and diabetic nephropathy.<xref ref-type="bibr" rid="article-17585.r4">[4]</xref>&#x000a0;They are often used as an ACE inhibitor therapy replacement for patients who cannot tolerate ACE inhibitors because&#x000a0;of the ACE inhibitor-induced chronic, non-productive cough.</p>
      </sec>
      <sec id="article-17585.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Renin secretion is by the juxtaglomerular cells of the kidneys and catalyzes the conversion of angiotensinogen to angiotensin I (ATI) in the liver. ATI&#x000a0;is converted to angiotensin II (ATII) by angiotensin-converting enzyme (ACE) and other non-ACE pathways.<xref ref-type="bibr" rid="article-17585.r2">[2]</xref></p>
        <p>ATII is the principal vasoactive peptide in the RAAS and acts on two receptors, AT1 and AT2. ATII activation of AT1 receptors causes increased blood pressure due to contraction of vascular smooth muscle, increased systemic vascular resistance, increased sympathetic activity, sodium (Na), and water retention due to increased Na reabsorption in the proximal convoluted tubule.<xref ref-type="bibr" rid="article-17585.r3">[3]</xref> Sodium reabsorption in the proximal convoluted tubule is a direct&#x000a0;result of ATII and indirectly by increased aldosterone production in the adrenal cortex, promoting distal Na reabsorption. Chronically high levels of ATII cause smooth muscle and cardiac muscle cell growth and proliferation, endothelial dysfunction, platelet aggregation, enhanced inflammatory responses, and mediation of apoptosis. On the other hand, the effects of ATII binding to AT2 receptors result in vasodilatation due to increased production of nitrous oxide and bradykinin.<xref ref-type="bibr" rid="article-17585.r5">[5]</xref> Furthermore, activation of AT2 receptors leads to renal sodium excretion. Agonism at AT2 receptors has anti-proliferative and cardiovascular protective effects.<xref ref-type="bibr" rid="article-17585.r3">[3]</xref></p>
        <p>RAAS system blockade can take place at several levels. RAAS-blockers include direct renin inhibitors (DRIs), which block the production of renin, ACEIs block conversion of AT1 to AT2 by blocking the angiotensin-converting enzyme, ARBs antagonize the effect of AII on AT1 receptors, and aldosterone antagonists block the effect of aldosterone.<xref ref-type="bibr" rid="article-17585.r6">[6]</xref><xref ref-type="bibr" rid="article-17585.r7">[7]</xref></p>
      </sec>
      <sec id="article-17585.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Indications for the use of ARBs are similar to those for ACEIs. However, in patients who cannot tolerate ACEI therapy due to an ACEI-induced cough or angioneurotic edema, ARB therapy is appropriate and suggested as an alternative.&#x000a0;Currently available angiotensin receptor blockers, their FDA approved indications, and dosing for these indications are&#x000a0;as follows:</p>
        <p>
<bold>Azilsartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 40 and 80 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 20 mg by mouth once daily, maximum daily dose: 80 mg</p>
          </list-item>
        </list>
        <p>
<bold>Candesartan&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 4 mg, 8 mg, 16 mg, 32 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 16 mg by mouth once daily, maximum daily dose: 32 mg</p>
          </list-item>
          <list-item>
            <p>Heart failure: Initial dose: 4&#x000a0;to 8 mg by mouth once daily, maximum daily dose: 32 mg</p>
          </list-item>
        </list>
        <p>
<bold>Eprosartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 400 mg, 600 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 600 mg by mouth once daily, maximum daily dose: 900 mg</p>
          </list-item>
        </list>
        <p>
<bold>Irbesartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 75 mg, 150 mg, 300 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 150 mg by mouth once daily, maximum daily dose: 300 mg</p>
          </list-item>
          <list-item>
            <p>Diabetic nephropathy: Initial dose: 75 mg by mouth once daily, maximum daily dose: 300 mg</p>
          </list-item>
        </list>
        <p>
<bold>Losartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 25 mg, 50 mg, and 10 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 50 mg by mouth once daily, maximum daily dose: 100 mg</p>
          </list-item>
          <list-item>
            <p>For stroke prevention in hypertensive patients with a history of left ventricular hypertrophy (this does not apply to African-American patients): Initial dose: 50 mg by mouth once daily, maximum daily dose: 100 mg</p>
          </list-item>
          <list-item>
            <p>For the treatment of proteinuria or diabetic nephropathy: Initial dose: 50 mg by mouth once daily, maximum daily dose: 100 mg</p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Olmesartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 5 mg, 20 mg, and 40 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 20 mg by mouth once daily. Maximum daily dose: 40 mg</p>
          </list-item>
        </list>
        <p>
<bold>Telmisartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 20 mg, 40 mg, and 80 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose: 40 mg by mouth once daily, maximum daily dose: 80 mg</p>
          </list-item>
          <list-item>
            <p>To reduce cardiovascular-related mortality in adults age 55 years and older who have risk factors for serious cardiovascular events and cannot tolerate ACEI, stroke prophylaxis, and myocardial infarction prophylaxis.</p>
          </list-item>
          <list-item>
            <p>Initial dose: 80 mg by mouth once daily, maximum daily dose: 80 mg</p>
          </list-item>
        </list>
        <p>
<bold>Valsartan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available as 40mg, 80 mg, 160 mg and 320 mg tablet</p>
          </list-item>
        </list>
        <p>Dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension: Initial dose 80-160mg by mouth once daily, a maximum daily dose of 320 mg</p>
          </list-item>
          <list-item>
            <p>For reducing cardiovascular mortality in otherwise stable patients with a history of left ventricular failure and or left ventricular dysfunction (LVD) following acute myocardial infarction.</p>
          </list-item>
          <list-item>
            <p>Heart failure: Initial dose: 20 mg by mouth twice a day, maximum daily dose: 160 mg bid</p>
          </list-item>
          <list-item>
            <p>Heart failure: Initial dose: 20 to 40 mg by mouth twice a day, maximum dose of 160 mg bid</p>
          </list-item>
        </list>
        <p>ARBs are available combined with other medications. A few examples are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Valsartan and amlodipine</p>
          </list-item>
          <list-item>
            <p>Irbesartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Losartan potassium and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Valsartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Valsartan and nebivolol</p>
          </list-item>
        </list>
        <p>The combination of valsartan and sacubitril (neprilysin inhibitor) is available and approved for reducing the risk of cardiovascular death, decreasing hospitalization for heart failure in patients with chronic heart failure (NYHA Class II through IV) and patients with reduced ejection fraction.</p>
        <p>A few caveats to remember about the use of ARBs:</p>
        <p>In patients with volume depletion or in those who are on diuretics, correct volume depletion before starting these agents or start with a lower dose.</p>
        <p>Consider using a lower dose in geriatric patients.</p>
        <p>Consider every 12-hour dosing in patients who experience diminished blood pressure response towards the end of a 24-hour dosing interval.</p>
      </sec>
      <sec id="article-17585.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>ARBs are generally well tolerated and have a low incidence of side effects. The incidence of angioedema and cough with ARBs is less than with ACEIs because ARBs do not increase bradykinin levels though reports of rare cases of both exist with patients using ARBs. ARBs can cause hypotension and/or renal failure in patients whose arterial blood pressure or renal function is highly dependent on the RAAS. For this reason, these drugs are contraindicated in patients with bilateral renal artery stenosis or patients with heart failure who have hypotension.<xref ref-type="bibr" rid="article-17585.r8">[8]</xref><xref ref-type="bibr" rid="article-17585.r9">[9]</xref></p>
      </sec>
      <sec id="article-17585.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>ARB therapy and ACE use during pregnancy reduce perfusion of the fetal kidneys and correlate with renal dysgenesis, fetal oliguric or anuric renal failure, oligohydramnios, skeletal or skull deformities, pulmonary hypoplasia, and death of the fetus. ARBs are FDA classified as a category D risk during pregnancy, and patients who may become pregnant while taking ARBs should understand the importance of birth control. These patients should be educated on different options to control blood pressure should they become pregnant and need to switch to a different antihypertensive therapy. For patients who have become pregnant or think they have become pregnant, ARB therapy should be stopped immediately unless such treatment is considered life-saving for the mother.<xref ref-type="bibr" rid="article-17585.r9">[9]</xref></p>
        <p>No published evidence exists on the safe use of ARBs during breastfeeding, and the effects of potential exposure to a nursing infant are unknown. Newborn infants are at theoretical risk of hypotension due to ARB as these drugs may end up in breast milk. A decision to continue or stop breastfeeding is a necessary discussion between the primary care provider and the patient.&#x000a0;&#x000a0;</p>
        <p>ARBs may lead to hyperkalemia in patients with renal disease or patients taking agents likely to cause hyperkalemia (K+ supplements, K+ sparing diuretics, ACEIs, DRIs, non-steroidal anti-inflammatory agents); care is necessary&#x000a0;when considering prescribing ARBs in these patients, or they should be avoided altogether.</p>
        <p>ARBs potentiate the blood pressure-lowering effect of other antihypertensive drugs and may require adjusting the drug dosage of either the ARB or the other antihypertensive drugs.</p>
        <p>The use of ARBs, along with ACEIs or DRIs, comes with a higher incidence of hypotension, acute renal failure, or hyperkalemia. The combined use of these agents is no longer a recommendation and should be avoided.</p>
        <p>There are rare reported cases of adverse effects, including urticaria, anaphylaxis, vasculitis, neutropenia, leukopenia, liver function test abnormalities, and others.<xref ref-type="bibr" rid="article-17585.r10">[10]</xref></p>
      </sec>
      <sec id="article-17585.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>ARB therapy puts the patient at an increased risk for hypotension, renal impairment, and hyperkalemia. Therefore patient's blood pressure, renal function, and serum electrolytes should be monitored closely for the duration of ARB use.<xref ref-type="bibr" rid="article-17585.r11">[11]</xref>&#x000a0;Primary care providers should pay specific attention to the full medication list. Lithium concentrations may increase with the concomitant use of ARBs.<xref ref-type="bibr" rid="article-17585.r12">[12]</xref><xref ref-type="bibr" rid="article-17585.r13">[13]</xref></p>
      </sec>
      <sec id="article-17585.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The proper and successful management of hypertension often requires a whole-person approach that should include&#x000a0;clinicians, mid-level practitioners, nurses, the primary care provider, pharmacists, and specialists to treat a patient&#x000a0;with a wide variety of different etiologies of high blood pressure. It may require diversified help from medical specialties&#x000a0;since diabetes, heart failure, renal compromise, and obesity often accompany hypertension. This demonstrates an interprofessional team approach to patient care. Although&#x000a0;ARB therapy is one of many options in treating hypertension and concomitant conditions of diabetes and or heart failure, early treatment in the face of such a diagnosis has proven to have great success in treating hypertension.<xref ref-type="bibr" rid="article-17585.r2">[2]</xref> [Level 1] If possible,&#x000a0;high blood pressure should be diagnosed and treated early as heart disease continues to affect patients at a younger age.<xref ref-type="bibr" rid="article-17585.r14">[14]</xref></p>
        <p>When initiating ARB therapy, a pharmacist should also have involvement to verify dosing, check for drug interactions and contraindications, counsel the patient, and report back to the prescriber if there are any areas of concern. Likewise, nursing should answer patient questions, instruct them on proper administration, and maintain open communication with the prescriber and the pharmacist. This interprofessional team methodology ensures optimal patient results from ARB treatment. [Level 5]</p>
        <p>Along with proper pharmacotherapy in treating hypertension, physicians overseeing ARB therapy should encourage patients to begin a weight loss program. Decreased inflammation and a reduction in systolic hypertension are all possible&#x000a0;benefits of patients controlling their weight.<xref ref-type="bibr" rid="article-17585.r15">[15]</xref> [Level 2]</p>
      </sec>
      <sec id="article-17585.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17585&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17585">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17585/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17585">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17585.s10">
        <title>References</title>
        <ref id="article-17585.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez-Hern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sosa-Canache</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armas-Hern&#x000e1;ndez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Armas-Padilla</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cammarata</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II receptor antagonists role in arterial hypertension.</article-title>
            <source>J Hum Hypertens</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>16 Suppl 1</volume>
            <fpage>S93</fpage>
            <page-range>S93-9</page-range>
            <pub-id pub-id-type="pmid">11986904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Angiotensin receptor blockers in cardiovascular disease.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-308</page-range>
            <pub-id pub-id-type="pmid">16915347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cernes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mashavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zimlichman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Differential clinical profile of candesartan compared to other angiotensin receptor blockers.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2011</year>
            <volume>7</volume>
            <fpage>749</fpage>
            <page-range>749-59</page-range>
            <pub-id pub-id-type="pmid">22241949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <chapter-title>Angiotensin II Receptor Antagonists</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Latini</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?</article-title>
            <source>Blood Press</source>
            <year>2002</year>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>328</fpage>
            <page-range>328-38</page-range>
            <pub-id pub-id-type="pmid">12523675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2002</year>
            <season>Fall</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>183</fpage>
            <page-range>183-91</page-range>
            <pub-id pub-id-type="pmid">12556752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malacco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santonastaso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Var&#x000ec;</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Gargiulo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spagnuolo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bertocchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palatini</surname>
                <given-names>P</given-names>
              </name>
              <collab>Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study</collab>
            </person-group>
            <article-title>Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.</article-title>
            <source>Clin Ther</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-65</page-range>
            <pub-id pub-id-type="pmid">15262456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodgers</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II-receptor blockers: clinical relevance and therapeutic role.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2001</year>
            <month>Apr</month>
            <day>15</day>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>671</fpage>
            <page-range>671-83</page-range>
            <pub-id pub-id-type="pmid">11329759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ventura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maraschini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Aloja</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirchmayer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lega</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug prescribing during pregnancy in a central region of Italy, 2008-2012.</article-title>
            <source>BMC Public Health</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>623</fpage>
            <pub-id pub-id-type="pmid">29764430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Islander</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nordang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karawajczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Terreehorst</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Baranova</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Hugosson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sk&#x000f6;ldefors</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maitland-van der Zee</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Alfirevic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hallberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>477</fpage>
            <page-range>477-81</page-range>
            <pub-id pub-id-type="pmid">24960520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin receptor blockers: current status and future prospects.</article-title>
            <source>Indian Heart J</source>
            <year>2007</year>
            <season>Nov-Dec</season>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>443</fpage>
            <page-range>443-53</page-range>
            <pub-id pub-id-type="pmid">19151457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balit</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gilmore</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Unintentional paediatric ingestions of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists.</article-title>
            <source>J Paediatr Child Health</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>686</fpage>
            <page-range>686-8</page-range>
            <pub-id pub-id-type="pmid">17854454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoffmann-Walbeck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stedtler</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ceschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>F&#x000e4;rber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Genser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seidel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deters</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II antagonists - an assessment of their acute toxicity.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>429</fpage>
            <page-range>429-34</page-range>
            <pub-id pub-id-type="pmid">23692319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gohlke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Verschuren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Albus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benlian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boysen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cifkova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ebrahim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Germano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karadeniz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mezzani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ryden</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Syv&#x000e4;nne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholte op Reimer</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Vrints</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <collab>European Association for Cardiovascular Prevention &#x00026; Rehabilitation (EACPR)</collab>
              <collab>ESC Committee for Practice Guidelines (CPG)</collab>
            </person-group>
            <article-title>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).</article-title>
            <source>Eur Heart J</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>13</issue>
            <fpage>1635</fpage>
            <page-range>1635-701</page-range>
            <pub-id pub-id-type="pmid">22555213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17585.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foulquier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Namsolleck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Recarti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steckelings</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.</article-title>
            <source>Drugs</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">26631237</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
